24.02.2012 09:05 Uhr, Quelle: Presseportal

New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studies

Astellas Pharma Europe Limited: Paris (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., European subsidiary of Tokyo-based Astellas Pharma Inc. today announced results from three separate clinical trials that further support the efficacy and tolerability of mirabegron. Mirabegron, a

Weiterlesen bei Presseportal

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz